Fulcrum Therapeutics Announces Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). Th...
Home/KnloSights/Clinical Trial Updates/Fulcrum Therapeutics Announces Positive Phase 1b Results for Pociredir in Sickle Cell Disease